190 related articles for article (PubMed ID: 25319617)
1. Molecular insights on analogs of HIV PR inhibitors toward HTLV-1 PR through QM/MM interactions and molecular dynamics studies: comparative structure analysis of wild and mutant HTLV-1 PR.
Selvaraj C; Singh P; Singh SK
J Mol Recognit; 2014 Dec; 27(12):696-706. PubMed ID: 25319617
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies and comparative analysis on structurally similar HTLV and HIV protease using HIV-PR inhibitors.
Selvaraj C; Singh P; Singh SK
J Recept Signal Transduct Res; 2014 Oct; 34(5):361-71. PubMed ID: 24694004
[TBL] [Abstract][Full Text] [Related]
3. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
Demir A; Oguariri RM; Magis A; Ostrov DA; Imamichi T; Dunn BM
Antivir Ther; 2012; 17(5):883-92. PubMed ID: 22436331
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
5. Molecular insights of protein contour recognition with ligand pharmacophoric sites through combinatorial library design and MD simulation in validating HTLV-1 PR inhibitors.
Selvaraj C; Omer A; Singh P; Singh SK
Mol Biosyst; 2015 Jan; 11(1):178-89. PubMed ID: 25335799
[TBL] [Abstract][Full Text] [Related]
6. Privileged Structures Meet Human T-Cell Leukemia Virus-1 (HTLV-1): C2-Symmetric 3,4-Disubstituted Pyrrolidines as Nonpeptidic HTLV-1 Protease Inhibitors.
Kuhnert M; Blum A; Steuber H; Diederich WE
J Med Chem; 2015 Jun; 58(11):4845-50. PubMed ID: 26000468
[TBL] [Abstract][Full Text] [Related]
7. Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease.
Ma S; Vogt KA; Petrillo N; Ruhoff AJ
Comput Biol Chem; 2015 Jun; 56():61-70. PubMed ID: 25889320
[TBL] [Abstract][Full Text] [Related]
8. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.
Kádas J; Weber IT; Bagossi P; Miklóssy G; Boross P; Oroszlan S; Tözsér J
J Biol Chem; 2004 Jun; 279(26):27148-57. PubMed ID: 15102858
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.
Rücker P; Horn AH; Meiselbach H; Sticht H
J Mol Model; 2011 Oct; 17(10):2693-705. PubMed ID: 21279524
[TBL] [Abstract][Full Text] [Related]
10. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.
Tözsér J; Weber IT
Curr Pharm Des; 2007; 13(12):1285-94. PubMed ID: 17504236
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.
Nguyen JT; Kato K; Hidaka K; Kumada HO; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2011 Apr; 21(8):2425-9. PubMed ID: 21392990
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.
Li M; Laco GS; Jaskolski M; Rozycki J; Alexandratos J; Wlodawer A; Gustchina A
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18332-7. PubMed ID: 16352712
[TBL] [Abstract][Full Text] [Related]
13. Substrates and inhibitors of human T-cell leukemia virus type I protease.
Ding YS; Rich DH; Ikeda RA
Biochemistry; 1998 Dec; 37(50):17514-8. PubMed ID: 9860866
[TBL] [Abstract][Full Text] [Related]
14. Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
Leonis G; Czyżnikowska Ż; Megariotis G; Reis H; Papadopoulos MG
J Chem Inf Model; 2012 Jun; 52(6):1542-58. PubMed ID: 22587384
[TBL] [Abstract][Full Text] [Related]
15. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase.
Hrusková-Heidingsfeldová O; Bláha I; Urban J; Strop P; Pichová I
Leukemia; 1997 Apr; 11 Suppl 3():45-6. PubMed ID: 9209292
[TBL] [Abstract][Full Text] [Related]
16. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
Towler EM; Gulnik SV; Bhat TN; Xie D; Gustschina E; Sumpter TR; Robertson N; Jones C; Sauter M; Mueller-Lantzsch N; Debouck C; Erickson JW
Biochemistry; 1998 Dec; 37(49):17137-44. PubMed ID: 9860826
[TBL] [Abstract][Full Text] [Related]
18. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases.
Sperka T; Miklóssy G; Tie Y; Bagossi P; Zahuczky G; Boross P; Matúz K; Harrison RW; Weber IT; Tözsér J
J Gen Virol; 2007 Jul; 88(Pt 7):2052-2063. PubMed ID: 17554040
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting HTLV-1 Protease: A Viable Antiviral Target.
Lockbaum GJ; Henes M; Talledge N; Rusere LN; Kosovrasti K; Nalivaika EA; Somasundaran M; Ali A; Mansky LM; Kurt Yilmaz N; Schiffer CA
ACS Chem Biol; 2021 Mar; 16(3):529-538. PubMed ID: 33619959
[TBL] [Abstract][Full Text] [Related]
20. Development of [Ile⁴⁰]HTLV-I protease inhibition assay using novel fluorogenic and chromogenic substrate.
Kumada HO; Nguyen JT; Kakizawa T; Hidaka K; Kimura T; Hayashi Y; Kiso Y
J Pept Sci; 2011 Aug; 17(8):569-75. PubMed ID: 21574213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
